Month: October 2020

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.65202-50-8,Methyl 6-chloropyridazine-3-carboxylate,as a common compound, the synthetic route is as follows.

Methyl -chloropyridazine-S-carboxylate (S49, 34 mg, 0.19 mmol), 6-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)picolinonitrile (45 mg, 0.19 mmol), K2CO3 (51 mg, 0.39 mmol), and (Ph3P)4Pd (34 mg, 0.029 mmol) were slurried in DMF (0.3 M). The reaction vessel was evacuated and refilled with argon three times. The mixture was warmed at 85 ¡ãC for 16 h. The reaction mixture was cooled and diluted with EtOAc, washed with 9: 1 NH4OH:saturated aqueous NH4Cl and saturated aqueous NaCl, and then dried over Na2SO4. Evaporation yielded the crude product that was purified by flash chromatography (SiO2, 1.5 x 14 cm, 20-100percent EtOAc- hexanes) to afford the title compound (25 mg, 53percent) as a white solid: 1H NMR (CDCl3, 600 MHz) 5 9.03 (d, IH, J= 8.1 Hz), 8.75 (d, IH, J= 8.7 Hz), 8.36 (d, IH, J= 8.7 Hz), 8.09 (t, IH, J = 7.9 Hz), 7.84 (d, IH, J= 7.6 Hz), 4.12 (s, 3H); 13C NMR (CDCl3, 150 MHz) delta 164.4, 158.2, 154.4, 151.7, 138.7, 133.9, 129.8, 128.7, 125.5, 125.4, 1 16.9, 53.6; HRMS-ESI-TOF m/z 241.0721 ([M+H]+, C12H8N4O2 requires 241.0720)., 65202-50-8

The synthetic route of 65202-50-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; THE SCRIPPS RESEARCH INSTITUTE; BOGER, Dale, L.; WO2010/5572; (2010); A2;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

141-30-0, 3,6-Dichloropyridazine is a pyridazine compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Intermediate D (1 eq.), silver nitrate (1 eq.), and the appropriate carboxylic acid (1 eq.) were dissolved in water. The reaction mixture was heated to 50C and concentrated sulfuric acid (3eq.) was added. The reaction mixture was heated to 60C and aqueous ammonium per sulphate (3eq.) was added. The reaction mixture was kept at 70C for 30 minutes before cooling to room temperature. pH was adjusted to 8 with 1 N NaOH. The mixture was extracted with ethyl acetate, dried over MgS04, filtered and evaporated. The residue was purified by chromatography on silica gel to provide the desired mono or di substituted 3,6- dichloro-[1 ,2,4]triazolo[4,3-b]pyridazine.Reaction of intermediate D with propionic acid gave a mixture of compounds. Purification on silica gel yielded 6% of 3,6-dichloro-7,8-diethyl-[1 ,2,4]triazolo[4,3-b]pyridazine and 5% of 3,6-dichloro-8-ethyl-[1 ,2,4]triazolo[4,3-b]pyridazine. These intermediates were used to prepare Cpd.5-12 and Cpd.5-13 respectively.Intermediate of Cpd.5-8 was obtained in the same manner with 15% yield.This protocol was also used to prepare intermediate of Cpd.5-14, Cpd.5-1 1 from 3,6- dichloropyridazine with appropriate carboxylic acid with 42% and 81 % yields respectively.

141-30-0, The synthetic route of 141-30-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; GENFIT; BOUROTTE, Maryline; DELHOMEL, Jean-Francois; DUBERNET, Mathieu; GOUY, Marie-Helene; WO2013/45519; (2013); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.141-30-0,3,6-Dichloropyridazine,as a common compound, the synthetic route is as follows.

Hydroiodic acid (250mL) was added to a mixture of 3, 6-dichloropyridazine (149g, 1 mol CAS:[135034-10- 5]) and Nal (180g, 1 .2mol) in 500mL of CHCI3. After the addition, the mixture was stirred at ambient temperature for 24h, and poured into water and extracted with dichloromethane three times. The combined organic layers were dried over sodium sulfate, filtered and concentrated in vacuo to give 3- chloro-6-iodopyridazine. H-NMR (400Mz, DMSO-d6) delta: 7.63 (d, 1 H), 8.16 (d, 1 H).

141-30-0, As the paragraph descriping shows that 141-30-0 is playing an increasingly important role.

Reference£º
Patent; SYNGENTA CROP PROTECTION AG; SYNGENTA (CHINA) INVESTMENT CO., LTD.; EDMUNDS, Andrew; HALL, Roger Graham; MUEHLEBACH, Michel; EMERY, Daniel; JUNG, Pierre Joseph Marcel; LU, Long; WU, Yaming; CHEN, Ruifang; (156 pag.)WO2016/169886; (2016); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

17973-86-3, 3,6-Dibromopyridazine is a pyridazine compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

SYNTHETIC EXAMPLE 4 Synthesis of N-(2-nitrobenzoyl)-N’-[4-(6-bromo-3-pyridazinyloxy)-3-nitrophenyl]urea (Compound No. 7) 3.0 g of 3,6-dibromopyridazine was dissolved in 15 ml of dimethyl sulfoxide. To this solution, a mixture of 2.0 g of 4-amino-2-nitrophenol, 3.6 g of potassium carbonate and 10 ml of water was added and, after flushing with nitrogen, the mixture was reacted at a temperature of from 100 to 110 C. for 2 hours. After the completion of the reaction, the reaction product was cooled and poured into water, and then extracted with methylene chloride. The extract layer was washed with an aqueous sodium hydroxide solution and then with water, and dried over anhydrous sodium sulfate. Then, the solvent was distilled off, whereby 2.4 g of 4-(6-bromo-3-pyridazinyloxy)-3-nitroaniline was obtained., 17973-86-3

The synthetic route of 17973-86-3 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Ishihara Sangyo Kaisha Ltd.; US4677111; (1987); A;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.13327-27-0,6-Methylpyridazin-3(2H)-one,as a common compound, the synthetic route is as follows.

To 6-methylpyridazin-3(2H)-one (0.510 g, 4.63 mmol) was added 5 N sodium hydroxide solution (1.85 mL) followed by 2-bromopropanoic acid (0.709 g, 4.63 mmol). The reaction mixture was heated at 90 C. for 1 h. After cooled down to ambient temperature, 2 M hydrochloric acid (5.0 mL) was added and the reaction mixture was directly purified by reverse phase HPLC (TMC Pro-Pac C18; 8-20% 0.1% trifluoroacetic acid in acetonitrile/0.1% trifluoroacetic acid in water gradient). The O-alkylation product was eluted fast. The pure fractions were collected and lyophilized overnight to afford the two title compounds. LC/MS 183.2 (M+1). 2-[3-methyl-6-oxopyridazin-1(6H)-yl]propanoic acid (i-42): 1H NMR (DMSO-d6): delta 7.34 (d, J=9.7 Hz, 1H), 6.88 (d, J=9.4 Hz, 1H), 5.30 (q, J=7.3 Hz, 1H), 2.26 (s, 3H), 1.49 (d, J=7.3 Hz, 3H). 2-[(6-methylpyridazin-3-yl)oxy]propanoic acid (i-43): 1H NMR (DMSO-d6): delta 8.36 (d, J=9.0 Hz, 1H), 7.90 (d, J=9.2 Hz, 1H), 6.00 (q, J=6.6 Hz, 1H), 2.90 (s, 3H), 1.73 (d, J=6.6 Hz, 3H)., 13327-27-0

As the paragraph descriping shows that 13327-27-0 is playing an increasingly important role.

Reference£º
Patent; Berger, Richard; Chang, Lehua; Edmondson, Scott D.; Goble, Stephen D.; Ha, Sookhee Nicole; Kar, Nam Fung; Kopka, Ihor E.; Li, Bing; Morriello, Gregori J.; Moyes, Chris R.; Shen, Dong-Ming; Wang, Liping; Zhu, Cheng; US2009/253705; (2009); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

187973-60-0, 6-Iodopyridazin-3-amine is a pyridazine compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Toa mixture of 6-iodopyridazin-3-amine (500 mg, 2.26 mmol), NaHC03(230 mg, 2.71 mmol) in MeOH (5 mL) was added bromine (117 mu, 2.26 mmol)dropwise. The resulting mixture was stirred at room temperature for 16 hrs. Thesolution was filtered and the filtrate concentrated in vacuo. The residue wasdissolved in water, and the product extracted with EtOAc (3 times). The organiclayers were combined, dried ( a2S04) and concentrated invacuo to give a dark red solid which was purified by flash silicachromatography (eluent: 20% EtOAc :Hexane) to give a 60:40 mixture of the titlecompounds as an off white solid (250 mg); H NMR (400 MHz, CDC13) delta5.49 (s, 4H), 7.66 (s, 1H), 7.81 (s, 1H)Toa stirred solution of a mixture of 4,6-dibromopyridazin-3-amine and 4-bromo-6-iodopyridazin-3-amine (10 g, compounds not separated in previous step,estimated 34 mmol) in methanol (90 mL) was added solid sodium methoxide (3.6 g,67 mmol) at room temperature and the reaction mixture stirred at 90C for16hrs. More sodium methoxide was added regularly until all starting materialhad been consumed. The cooled solution was concentrated in vacuo and theresidue poured into water (200 mL). The resulting solution was extracted withEtOAc three times and the organic layers were combined, dried (MgSC^), andconcentrated in vacuo. The residue was purified by silica column chromatography(eluent: chloroform: methanol (98:0.2 to 90:10) to afford the title mixture ofmethoxy ethers (3.0g, taken into next steps without further purification); HNMR (400 MHz, CDC13) delta 3.90 (s, 3H), 3.92 (s, 3H), 5.05 (m, 3H),6.75 (s, 1H), 6.91 (s, 1H).To a stirred solution of (6-bromo-4-methoxypyridazin-3-amine and 6-iodo-4-methoxy- pyridazin-3 -amine (0.8 g, mixture not separated in previous step, estimated 3.92 mmol) in pyridine (9 mL) was added (3,5-dichlorophenyl)methanesulfonyl chloride (1.02 g, 3.92 mmol) at room temperature and the mixture stirred for 16 hrs. Water was then added and the mixture extracted with EtOAc (3x 150 mL). The combined organic layers were washed with more water and brine, then concentrated and purified by flash silica chromatography (eluent: 1% MeOH:DCM) to afford a mixture of methoxy ethers (250mg). To this mixture in DCM (5 mL) was added neat boron tribromide (166 mu, 1.76 mmol) and the mixture stirred for 3h before being diluted with DCM and neutralised with saturated NaHC03 (pH 7). The phases were separated and the aqueous phase extracted with DCM and EtOAc. The combined organic layers were dried (MgSC^), the mixture filtered and the filtrate concentrated to dryness to yield an oil which was purified by automated reverse phase HPLC (low pH method) to afford 1 -(3,5-dichlorophenyl)-N-(4- hydroxy-6-iodopyridazin-3-yl)methanesulfonamide (22 mg, 16%) and -(6-bromo-4- hydroxypyridazin-3-yl)-l-(3,5)-dichlorophenyl)methanesulfonamide (22 mg, 18%)., 187973-60-0

The synthetic route of 187973-60-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; ACTIVE BIOTECH AB; FRITZSON, Ingela; LIBERG, David; EAST, Stephen; MACKINNON, Colin; PREVOST, Natacha; WO2014/184234; (2014); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

5096-73-1,5096-73-1, 6-Chloropyridazine-3-carboxylic acid is a pyridazine compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

6-(4-Chloro-phenylamino)-pyridazine-3-carboxylic acidA mixture of 6-chloro-pyridazine-3-carboxylic acid (80% pure, 400 mg, 2.02 mmol) and 4- chloro-aniline (523 mg, 4.06 mmol) in 1 ,2-DME (10 ml) was heated to 80 0C for 90 min in the microwave oven. The mixture was allowed to cool to RT and then concentrated in vacuo. Purification by flash chromatography (Hex/EtOAc 100:0 to 0:100) gave 6-(4-chloro- phenylamino)-pyridazine-3-carboxylic acid (50% pure, 330 mg, 33 %). UPLC (5-100% CH3CN): tR = 0.915 min, MS (ES-): 248 [M-1].

As the paragraph descriping shows that 5096-73-1 is playing an increasingly important role.

Reference£º
Patent; NOVARTIS AG; WO2008/128968; (2008); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.84956-71-8,2-(tert-Butyl)-4,5-dichloropyridazin-3(2H)-one,as a common compound, the synthetic route is as follows.

84956-71-8, General procedure: A solution of the substituted pyridazinone and either a benzylic alcohol or benzylic bromide in dimethylformamide was treated with cesium carbonate then optionally heated to 55-80 C. After cooling to ambient temperature, the crude product was isolated as a solution in ethyl acetate, washed with water and aqueous sodium chloride then dried, filtered and concentrated. Subsequent purification by chromatography on silica afforded the title compound.

As the paragraph descriping shows that 84956-71-8 is playing an increasingly important role.

Reference£º
Patent; Lantheus Medical Imaging, Inc.; Cesati, Richard R.; Radeke, Heike S.; Pandey, Suresh K.; Purohit, Ajay; Robinson, Simon P.; US2015/196672; (2015); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.63001-30-9,Methyl 6-oxo-1,6-dihydropyridazine-3-carboxylate,as a common compound, the synthetic route is as follows.,63001-30-9

To a solution of methyl 6-oxo-lH-pyridazine-3-carboxylate (2.59 g, 1.0 eq, 16.64 mmol, from Combi-Blocks) and potassium acetate, KOAc (6.60 g, 4.0 eq) in 50 mL of acetic acid, glacial, cooled at 0 C, bromine, Br2 (2.54 mL, 2.96 eq), is added. After the addition the mixture is stirred at 80 C for 5 h. The mixture is poured on 200 mL of saturated Na2S203 water solution. The mixture is extracted with EtOAc (10 % THF, 3 times, 150 mL in total). The gathered organic layers are washed with 200 mL of 0.01 N HC1 water solution and 200 mL of brine and dried over Na2S04. After filtration the solvent is evaporated and the resulting crude is purified by flash column chromatography (Si02, DCM / EtOAc 95:5 to 0: 100) to afford the desired compound. LCMS: MW (calcd): 233; m/z MW (obsd): 235 (M+H).

The synthetic route of 63001-30-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; GALAPAGOS NV; MAMMOLITI, Oscar; JANSEN, Koen, Karel; PALISSE, Adeline, Marie, Elise; JOANNESSE, Caroline, Martine, Andree-Marie; MENET, Christel, Jeanne, Marie; ALLART, Brigitte; EL BKASSINY, Sandy; (186 pag.)WO2017/148787; (2017); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.65202-50-8,Methyl 6-chloropyridazine-3-carboxylate,as a common compound, the synthetic route is as follows.

65202-50-8, Methyl 6-{3-r(2-bromophenyl)oxylazetidin-l-yl}pyridazine-3-carboxylate; Into a flame-dried 100 mL round-bottom flask equipped with a magnetic stirring bar and under N2 was added methyl 6-chloropyridazine-3-carboxylate (848 mg, 4.91 mmol), 3- [(2-bromophenyl)oxy]azetidine hydrochloride (1.3 g, 4.91 mmol) and potassium carbonate (2.04 g, 14.7 mmol) in dioxane (30 mL). The reaction mixture was heated to reflux for 16 h overnight. The reaction mixture was cooled to room temperature and quenched with water (10 mL). The reaction mixture was concentrated and a beige solid precipitated out of solution. The solid was diluted with water (20 mL) and filtered through WhatmanNo.l paper on a Hirsch funnel, washing with water. The resulting beige solid was dried on the vacuum pump overnight, giving the desired product.MS (ESI, Q+) m/z 364 (M + 1, 79Br), 366 (M + 1, 81Br).

65202-50-8 Methyl 6-chloropyridazine-3-carboxylate 12379801, apyridazine compound, is more and more widely used in various fields.

Reference£º
Patent; MERCK FROSST CANADA LTD.; WO2007/143823; (2007); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem